Human CD4+CD8α+ Tregs induced by Faecalibacterium prausnitzii protect against intestinal inflammation.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
22 06 2022
Historique:
received: 02 09 2021
accepted: 06 05 2022
pubmed: 11 5 2022
medline: 24 6 2022
entrez: 10 5 2022
Statut: epublish

Résumé

Abundance of Faecalibacterium prausnitzii, a dominant bacterium of the human microbiota that exhibits antiinflammatory effects, is decreased in patients with inflammatory bowel diseases (IBD). In humans, colonic lamina propria contains IL-10-secreting, Foxp3- Tregs characterized by a double expression of CD4 and CD8α (DP8α) and a specificity for F. prausnitzii. This Treg subset is decreased in IBD. The in vivo effect of DP8α cells has not been evaluated yet to our knowledge. Here, using a humanized model of a NSG immunodeficient mouse strain that expresses the HLA D-related allele HLA-DR*0401 but not murine class II (NSG-Ab° DR4) molecules, we demonstrated a protective effect of a HLA-DR*0401-restricted DP8α Treg clone combined with F. prausnitzii administration in a colitis model. In a cohort of patients with IBD, we showed an independent association between the frequency of circulating DP8α cells and disease activity. Finally, we pointed out a positive correlation between F. prausnitzii-specific DP8α Tregs and the amount of F. prausnitzii in fecal microbiota in healthy individuals and patients with ileal Crohn's disease.

Identifiants

pubmed: 35536673
pii: 154722
doi: 10.1172/jci.insight.154722
pmc: PMC9309064
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Immunity. 2019 Jan 15;50(1):212-224.e4
pubmed: 30650377
Nature. 2013 Aug 8;500(7461):232-6
pubmed: 23842501
Clin J Gastroenterol. 2018 Feb;11(1):1-10
pubmed: 29285689
Mol Med Rep. 2019 Jul;20(1):25-32
pubmed: 31115531
Immunity. 2015 Jul 21;43(1):65-79
pubmed: 26141582
Appl Environ Microbiol. 1997 Jul;63(7):2802-13
pubmed: 9212428
Gastroenterology. 2010 Dec;139(6):1844-1854.e1
pubmed: 20816835
Inflamm Bowel Dis. 2014 Mar;20(3):417-30
pubmed: 24418903
World J Gastroenterol. 2016 Jun 14;22(22):5201-10
pubmed: 27298563
Nature. 2011 Jun 15;474(7351):307-17
pubmed: 21677747
PLoS One. 2014 Oct 02;9(10):e109146
pubmed: 25275569
Genome Med. 2020 Jun 30;12(1):58
pubmed: 32605650
Lab Invest. 1993 Aug;69(2):238-49
pubmed: 8350599
Nature. 2012 Nov 1;491(7422):119-24
pubmed: 23128233
Front Immunol. 2019 Feb 06;10:143
pubmed: 30787928
J Physiol. 2018 Sep;596(17):3869-3882
pubmed: 29806140
Gut. 2016 May;65(5):882
pubmed: 26669616
Inflamm Bowel Dis. 2009 Aug;15(8):1183-9
pubmed: 19235886
Nat Rev Gastroenterol Hepatol. 2020 Apr;17(4):223-237
pubmed: 32076145
Curr Opin Microbiol. 2013 Jun;16(3):255-61
pubmed: 23831042
Nat Genet. 2015 Sep;47(9):979-986
pubmed: 26192919
Clin Immunol. 2007 Dec;125(3):281-90
pubmed: 17897887
Semin Immunopathol. 2017 Feb;39(2):113-120
pubmed: 27646959
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6
pubmed: 18936492
Front Immunol. 2018 Apr 06;9:682
pubmed: 29686676
Nat Med. 2016 Jun;22(6):598-605
pubmed: 27158904
Gastroenterology. 2018 Oct;155(4):1205-1217
pubmed: 29981781
Nature. 2019 May;569(7758):655-662
pubmed: 31142855
Ann N Y Acad Sci. 2005 Jun;1051:218-28
pubmed: 16126962
Inflamm Bowel Dis. 2009 May;15(5):653-60
pubmed: 19023901
Blood. 2015 Jun 18;125(25):3886-95
pubmed: 25833964
Nat Immunol. 2007 Sep;8(9):931-41
pubmed: 17694059
Gut Microbes. 2020 Nov 9;12(1):1-16
pubmed: 33054518
World J Gastroenterol. 2015 Oct 28;21(40):11236-45
pubmed: 26523099
Cell Host Microbe. 2014 Mar 12;15(3):382-392
pubmed: 24629344
PLoS Biol. 2014 Apr 08;12(4):e1001833
pubmed: 24714093

Auteurs

Sothea Touch (S)

Sorbonne University, INSERM, Saint-Antoine Center of Research, Centre De Recherche scientifique Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint Antoine Hospital, Gastroenterology Department, Paris, France.
Paris Center for Microbiome Medicine, University Hospital Federations, Paris, France.

Emmanuelle Godefroy (E)

Nantes University, University of Angers, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France.

Nathalie Rolhion (N)

Sorbonne University, INSERM, Saint-Antoine Center of Research, Centre De Recherche scientifique Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint Antoine Hospital, Gastroenterology Department, Paris, France.
Paris Center for Microbiome Medicine, University Hospital Federations, Paris, France.

Camille Danne (C)

Sorbonne University, INSERM, Saint-Antoine Center of Research, Centre De Recherche scientifique Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint Antoine Hospital, Gastroenterology Department, Paris, France.
Paris Center for Microbiome Medicine, University Hospital Federations, Paris, France.
INRAE, UMR1319 Micalis and AgroParisTech, Jouy en Josas, France.

Cyriane Oeuvray (C)

Sorbonne University, INSERM, Saint-Antoine Center of Research, Centre De Recherche scientifique Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint Antoine Hospital, Gastroenterology Department, Paris, France.
Paris Center for Microbiome Medicine, University Hospital Federations, Paris, France.

Marjolène Straube (M)

Sorbonne University, INSERM, Saint-Antoine Center of Research, Centre De Recherche scientifique Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint Antoine Hospital, Gastroenterology Department, Paris, France.
Paris Center for Microbiome Medicine, University Hospital Federations, Paris, France.

Chloé Galbert (C)

Sorbonne University, INSERM, Saint-Antoine Center of Research, Centre De Recherche scientifique Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint Antoine Hospital, Gastroenterology Department, Paris, France.
Paris Center for Microbiome Medicine, University Hospital Federations, Paris, France.

Loïc Brot (L)

Sorbonne University, INSERM, Saint-Antoine Center of Research, Centre De Recherche scientifique Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint Antoine Hospital, Gastroenterology Department, Paris, France.
Paris Center for Microbiome Medicine, University Hospital Federations, Paris, France.

Iria Alonso Salgueiro (I)

Sorbonne University, INSERM, Saint-Antoine Center of Research, Centre De Recherche scientifique Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint Antoine Hospital, Gastroenterology Department, Paris, France.
Paris Center for Microbiome Medicine, University Hospital Federations, Paris, France.

Sead Chadi (S)

INRAE, UMR1319 Micalis and AgroParisTech, Jouy en Josas, France.

Tatiana Ledent (T)

Sorbonne University, INSERM, Saint-Antoine Center of Research, Centre De Recherche scientifique Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint Antoine Hospital, Gastroenterology Department, Paris, France.

Jean-Marc Chatel (JM)

INRAE, UMR1319 Micalis and AgroParisTech, Jouy en Josas, France.

Philippe Langella (P)

INRAE, UMR1319 Micalis and AgroParisTech, Jouy en Josas, France.

Francine Jotereau (F)

Nantes University, University of Angers, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France.

Frédéric Altare (F)

Nantes University, University of Angers, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France.

Harry Sokol (H)

Sorbonne University, INSERM, Saint-Antoine Center of Research, Centre De Recherche scientifique Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint Antoine Hospital, Gastroenterology Department, Paris, France.
Paris Center for Microbiome Medicine, University Hospital Federations, Paris, France.
INRAE, UMR1319 Micalis and AgroParisTech, Jouy en Josas, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH